Clinically Severe Obesity: A Better Understanding Of A Complex Condition, Improving Health Outcomes Through Effective Therapies, And Delivering A Comprehensive Clinical Pathway.
Funder
National Health and Medical Research Council
Funding Amount
$701,539.00
Summary
Clinically severe obesity impacts on the health of 7-8% or 1.5 million Australians, yet poor access to integrated effective care. This challenging area of healthcare is distorted by perceptions and beliefs that are frequently contrary to clinical and physiological research findings. Professor Dixon’s plan is to: 1) To learn more about clinically severe obesity, 2) improve the assessment and delivery of effective care, and 3) improve clinical capacity to better care for these Australians.
ADVANCE-ON: A Post-trial Observational Study Of ADVANCE
Funder
National Health and Medical Research Council
Funding Amount
$775,867.00
Summary
The ADVANCE (Action in Diabetes and Vascular Disease) study demonstrasted that intensive control of blood glucose only reduced kidney disease but that control of blood pressure reduced both cardiovascular and kidney disease. This 10-year post-trial follow up study will determine whether intensive control of blood glucose exerts cardiovascular benefits that emerge in the long term in patients with type 2 diabetes.
Fenofibrate And Microvascular Events In Type 1 Diabetes (FAME 1) Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,883,529.00
Summary
Diabetes is one of the commonest cause of blindness in adults. Vision loss, which is irreversible, is a most feared complication of diabetes. A blood fat lowering drug called fenofibrate, available in Australia, has been shown to reduce eye damage in people with Type 2 diabetes by 35-40%, and to prevent eye damage in Type 1 diabetic animal models. This study will evaluate the potential benefits of fenofibrate in 450 adults with Type 1 diabetes who have early diabetic eye damage.
The overall aim is to improve treatments and outcomes for people with osteoporosis. This will be achieved by better predicting those who are likely to fracture and subsequently those who do well post fracture from those who do poorly. Following an osteoporotic fracture there is an increased risk of re- fracture and of premature death. This research will define those risk factors for fracture, re-fracture and early death in a large group of men and women followed for over 20 years.
Defining the molecular and cellular mechanisms of beta cell dysfunction. This project will investigate the influence of environment in the functional adaptation and maladaptation of pancreatic beta cells in diabetes. The research will define the molecular and cellular mechanisms linking environmental triggers such as obesity, high fatty acid levels and hyperglycaemia to beta cell dedifferentiation and dysfunction.
Discovering Optimal Weight Loss Interventions To Prevent Osteoarthritis In Obesity Through The Lens Of Early Biomarkers: The TANGO Diet Trial
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Osteoarthritis (OA) is the most common type of arthritis, and an obese population increases the disease burden of OA. Weight-loss is the first line management for symptom relief but is unclear whether weight loss can prevent OA changes in the joint. Biological OA markers can pick up early disease changes long before any signs on routine X-ray. My research will look at the effect of weight loss by very low energy diet on early OA biomarker in patients with overweight or obesity.